New Firm Aims to Transform Trial Startup
CliniStart announced the company’s opening as a new services provider with specialty focus in clinical trial startup functions, specifically focused in the niche area of clinical trial contracting. The company manages all aspects of the clinical trial contract development and negotiations life cycle, as well as investigator grant budget processes with exceptional knowledge and skill.
Sam Searcy, CEO and key founder of CliniStart, previously cofounded Clintrax Global and served as a global contracting account leader for strategic partnerships with large pharma sponsors. “We believe that in the near future, CliniStart will be the preferred partner for clinical trial contract negotiations and investigator grant budget development for both pharmaceutical sponsors and industry CROs. Our services and software solutions will allow sponsors and CROs to focus on the crucial work of managing clinical trials.”
For more information, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
